OCTHF (Oxford Cannabinoid Technologies Holdings) ROCE % : -160.34% (As of Oct. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oxford Cannabinoid Technologies Holdings's annualized ROCE % for the quarter that ended in Oct. 2023 was -160.34%.

Oxford Cannabinoid Technologies Holdings ROCE % Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings ROCE % Chart

Oxford Cannabinoid Technologies Holdings Annual Data

Trend

May18

May19

May20

May21

Apr23

ROCE %

-412.69

-186.29

-44.53

-70.20

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
	May19	Nov19	May20	Nov20	May21	Nov21	Oct22	Apr23	Oct23
ROCE %	Get a 7-Day Free Trial				-34.77	-33.69	-87.20	-104.64	-160.34

Oxford Cannabinoid Technologies Holdings ROCE % Calculation

Oxford Cannabinoid Technologies Holdings's annualized ROCE % for the fiscal year that ended in Apr. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2023 )		(A: May. 2021 )		(A: Apr. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2023 )		(A: May. 2021 )		(A: Apr. 2023 )
	=	-8.76	/	( ( (21.425 - 1.339)	+	(5.599 - 0.727) )	/ 2 )
	=	-8.76	/	( (20.086	+	4.872)	/ 2 )
	=	-8.76	/	12.479
	=	-70.20 %

Oxford Cannabinoid Technologies Holdings's ROCE % of for the quarter that ended in Oct. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2023 )		(Q: Apr. 2023 )		(Q: Oct. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2023 )		(Q: Apr. 2023 )		(Q: Oct. 2023 )
	=	-5.81	/	( ( (5.599 - 0.727)	+	(3.398 - 1.023) )	/ 2 )
	=	-5.81	/	( ( 4.872	+	2.375 )	/ 2 )
	=	-5.81	/	3.6235
	=	-160.34 %

(1) Note: The EBIT data used here is two times the semi-annual (Oct. 2023) EBIT data.

Oxford Cannabinoid Technologies Holdings (OTCPK:OCTHF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oxford Cannabinoid Technologies Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Oxford Cannabinoid Technologies Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford Cannabinoid Technologies Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (OTCPK:OCTHF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT

Website

https://www.oxcantech.com

Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings Headlines

No Headlines